The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Open accessAbstract
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs in doses of at least 2 g/day, were more effective than placebo but no more effective than SASP for inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the efficacy and safety of 5-ASA preparations used for the treatment of mild to moderately active ulcerative colitis. OBJECTIVES: The primary objectives were to assess the efficacy, dose-responsiveness and safety of oral 5-ASA compared to placebo, SASP, or 5-ASA comparators for induction of remission in active ulcerative colitis. A secondary objective of this systematic review was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens. SEARCH METHODS: A computer-assisted literature search for relevant studies (inception to July 9, 2015) was performed using MEDLINE, EMBASE and the Cochrane Library. Review articles and conference proceedings were also searched to identify additional studies. SELECTION CRITERIA: Studies were accepted for analysis if they were randomized controlled clinical trials of parallel design, with a minimum treatment duration of four weeks. Studies of oral 5-ASA therapy for treatment of patients with active ulcerative colitis compared with placebo, SASP or other formulations of 5-ASA were considered for inclusion. Studies that compared once daily 5-ASA treatment with conventional dosing of 5-ASA (two or three times daily) and 5-ASA dose ranging studies were also considered for inclusion. DATA COLLECTION AND ANALYSIS: The outcomes of interest were the failure to induce global/clinical remission, global/clinical improvement, endoscopic remission, endoscopic improvement, adherence, adverse events, withdrawals due to adverse events, and withdrawals or exclusions after entry. Trials were separated into five comparison groups: 5-ASA versus placebo, 5-ASA versus sulfasalazine, once daily dosing versus conventional dosing, 5-ASA versus comparator 5-ASA, and 5-ASA dose-ranging. Placebo-controlled trials were subgrouped by dosage. SASP-controlled trials were subgrouped by 5-ASA/SASP mass ratios. Once daily versus conventional dosing studies were subgrouped by formulation. 5-ASA-controlled trials were subgrouped by common 5-ASA comparators (e.g. Asacol, Claversal, Salofalk and Pentasa). Dose-ranging studies were subgrouped by 5-ASA formulation. We calculated the relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. Data were analyzed on an intention-to-treat basis. MAIN RESULTS: Fifty-three studies (8548 patients) were included. The majority of included studies were rated as low risk of bias. 5-ASA was significantly superior to placebo with regard to all measured outcome variables. Seventy-one per cent of 5-ASA patients failed to enter clinical remission compared to 83% of placebo patients (RR 0.86, 95% CI 0.82 to 0.89). A dose-response trend for 5-ASA was also observed. No statistically significant differences in efficacy were found between 5-ASA and SASP. Fifty-four per cent of 5-ASA patients failed to enter remission compared to 58% of SASP patients (RR 0.90, 95% CI 0.77 to 1.04). No statistically significant differences in efficacy or adherence were found between once daily and conventionally dosed 5-ASA. Forty-five per cent of once daily patients failed to enter clinical remission compared to 48% of conventionally dosed patients (RR 0.94, 95% CI 0.83 to 1.07). Eight per cent of patients dosed once daily failed to adhere to their medication regimen compared to 6% of conventionally dosed patients (RR 1.36, 95% CI 0.64 to 2.86). There does not appear to be any difference in efficacy among the various 5-ASA formulations. Fifty per cent of patients in the 5-ASA group failed to enter remission compared to 52% of patients in the 5-ASA comparator group (RR 0.94, 95% CI 0.86 to 1.02). A pooled analysis of 3 studies (n = 1459 patients) studies found no statistically significant difference in clinical improvement between Asacol 4.8 g/day and 2.4 g/day used for the treatment of moderately active ulcerative colitis. Thirty-seven per cent of patients in the 4.8 g/day group failed to improve clinically compared to 41% of patients in the 2.4 g/day group (RR 0.89; 95% CI 0.78 to 1.01). Subgroup analysis indicated that patients with moderate disease may benefit from the higher dose of 4.8 g/day. One study compared (n = 123 patients) Pentasa 4 g/day to 2.25 g/day in patients with moderate disease. Twenty-five per cent of patients in the 4 g/day group failed to improve clinically compared to 57% of patients in the 2.25 g/day group (RR 0.44; 95% CI 0.27 to 0.71). A pooled analysis of two studies comparing MMX mesalamine 4.8 g/day to 2.4 g/day found no statistically significant difference in efficacy (RR 1.03,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
(2008) · Cited by 3,790
Loftus, E. V. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.063 · Cited by 3,117
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Ford Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1955) · BMJ · doi:10.1136/bmj.2.4947.1041 · Cited by 2,767
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Rembacken, B., Snelling, A., Hawkey, P., Chalmers, D., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,101
Rachmilewitz, D. (1989) · BMJ · doi:10.1136/bmj.298.6666.82 · Cited by 1,039
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
Khan, A. K. A., Piris, J., & Truelove, S. C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90831-5 · Cited by 814
KRUIS, W., SCHÜTZ, E., FRIC, P., FIXA, B., JUDMAIER, G., & STOLTE, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 775
Sutherland, L. R., Martin, F., Greer, S., Robinson, M., Greenberger, N., Saibil, F., Martin, T., Sparr, J., Prokipchuk, E., & Borgen, L. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90621-4 · Cited by 677
Interpreting results and drawing conclusions
Schünemann, H. J., Vist, G. E., Higgins, J. P., Santesso, N., Deeks, J. J., Glasziou, P., Akl, E. A., Guyatt, G. H., & on behalf of the Cochrane GRADEing Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch15 · Cited by 595
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis
Kane, S., Huo, D., Aikens, J., & Hanauer, S. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01383-9 · Cited by 569
Ardizzone, S., Maconi, G., Russo, A., Imbesi, V, Colombo, E., & Bianchi Porro, G. (2006) · Gut · doi:10.1136/gut.2005.068809 · Cited by 505
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
Self-citationTHE ROLE OF INTESTINAL BACTERIA IN THE METABOLISM OF SALICYLAZOSULFAPYRIDINE
PEPPERCORN, M. A., & GOLDMAN, P. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29238-2 · Cited by 450
Das, K. M., Eastwood, M. A., McManus, J. P. A., & Sircus, W. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309062891001 · Cited by 445
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
Kane, S. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)03245-2 · Cited by 429
Andrade, S. E., Walker, A. M., Gottlieb, L. K., Hollenberg, N. K., Testa, M. A., Saperia, G. M., & Platt, R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321703 · Cited by 379
Feuerstein, J. D., & Cheifetz, A. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.002 · Cited by 376
Diagnosis and classification of ulcerative colitis
Conrad, K., Roggenbuck, D., & Laass, M. W. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.028 · Cited by 368
SVARTZ, N. (1942) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1942.tb06841.x · Cited by 364
Marteau, P., Probert, C. S., Lindgren, S., Gassul, M., Tan, T. G., Dignass, A., Befrits, R., Midhagen, G., Rademaker, J., & Foldager, M. (2005) · Gut · doi:10.1136/gut.2004.060103 · Cited by 362
CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS
Misiewicz, J. J., Lennard-Jones, J. E., Connell, A. M., Baron, J. H., & Avery Jones, F. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90972-4 · Cited by 360
Extraintestinal manifestations and complications in inflammatory bowel diseases
Rothfuss, K., Stange, E. F., & Herrlinger, K. R. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.12.4819 · Cited by 359
Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Kamm, M. A., Sandborn, W. J., Gassull, M., Schreiber, S., Jackowski, L., Butler, T., Lyne, A., Stephenson, D., Palmen, M., & Joseph, R. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.011 · Cited by 352
Absorption, metabolism, and excretion of salicylazosulfapyridine in man
Schröder, H., & Campbell, D. E. S. (1972) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1972134539 · Cited by 323
(1995) · Gastroenterology · doi:10.1016/0016-5085(95)27940-7 · Cited by 322
Klotz, U., Maier, K., Fischer, C., & Heinkel, K. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032602 · Cited by 322
Hanauer, S. B., Sandborn, W. J., Kornbluth, A., Katz, S., Safdi, M., Woogen, S., Regalli, G., Yeh, C., Smith-Hall, N., & Ajayi, F. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00248.x · Cited by 322
Sinha, A., Nightingale, J. M. D., West, K. P., Berlanga-Acosta, J., & Playford, R. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013136 · Cited by 303
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Ford, A. C., Achkar, J.-P., Khan, K. J., Kane, S. V., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.67 · Cited by 295
Systematic review: adherence issues in the treatment of ulcerative colitis
KANE, S. V. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02809.x · Cited by 294
SULPHASALAZINE AND SALICYLAZOSULPHADIMIDINE IN ULCERATIVE COLITIS
Baron, J. H., Connell, A. M., Lennard-Jones, J. E., & Avery Jones, F. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92080-9 · Cited by 287
Predictors of Medication Adherence in Inflammatory Bowel Disease
Ediger, J. P., Walker, J. R., Graff, L., Lix, L., Clara, I., Rawsthorne, P., Rogala, L., Miller, N., McPhail, C., Deering, K., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01212.x · Cited by 277
Lichtenstein, G. R., Kamm, M. A., Boddu, P., Gubergrits, N., Lyne, A., Butler, T., Lees, K., Joseph, R. E., & Sandborn, W. J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.10.025 · Cited by 267
Hanauer, S., SCHWARTZ, J., ROBINSON, M. G., Roufail, W. M., Arora, S., Cello, J. P., & Safdi, M. A. (1993) · PubMed · Cited by 266
Tursi, A., Brandimarte, G., Giorgetti, G. M., Forti, G., Modeo, M. E., & Gigliobianco, A. (2004) · PubMed · Cited by 266
Shale, M. J., & Riley, S. A. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01648.x · Cited by 256
Sandborn, W. J., Travis, S., Moro, L., Jones, R., Gautille, T., Bagin, R., Huang, M., Yeung, P., & Ballard, E. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.003 · Cited by 247
Sandborn, W. J., & Hanauer, S. B. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01408.x · Cited by 247
Controlled trial of sulphasalazine in the treatment of ulcerative colitis
Dick, A. P., Grayson, M. J., Carpenter, R. G., & Petrie, A. (1964) · Gut · doi:10.1136/gut.5.5.437 · Cited by 243
A clinical review of recent findings in the epidemiology of inflammatory bowel disease
Long, M., & Ponder (2013) · Clinical Epidemiology · doi:10.2147/clep.s33961 · Cited by 238
Sutherland, L. R., May, G. R., & Shaffer, E. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00009 · Cited by 230
Feagan, B. G., Sandborn, W. J., D'Haens, G., Pola, S., McDonald, J. W. D., Rutgeerts, P., Munkholm, P., Mittmann, U., King, D., Wong, C. J., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.025 · Cited by 223
Self-citationRasmussen, S. N., Bondesen, S., Hvidberg, E. F., Hansen, S. H., Binder, V., Halskov, S., & Flachs, H. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80075-9 · Cited by 223
Kruis, W., Kiudelis, G., Racz, I., Gorelov, I. A., Pokrotnieks, J., Horynski, M., Batovsky, M., Kykal, J., Boehm, S., Greinwald, R., et al. (2009) · Gut · doi:10.1136/gut.2008.154302 · Cited by 204
Riley, S. A., Mani, V, Goodman, M. J., Herd, M. E., Dutt, S., & Turnberg, L. A. (1988) · Gut · doi:10.1136/gut.29.5.669 · Cited by 193
Green, J. R. B., Lobo, A. J., Holdsworth, C. D., Leicester, R. J., Gibson, J. A., Kerr, G. D., Hodgson, H. J. F., Parkins, K. J., & Taylor, M. D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70627-4 · Cited by 191
An oral preparation to release drugs in the human colon.
Dew, M., Hughes, P., Lee, M., Evans, B., & Rhodes, J. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01999.x · Cited by 186
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Sutherland, L. R., & MacDonald, J. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub2 · Cited by 184
Self-citationOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Sutherland, L. R., & MacDonald, J. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub2 · Cited by 178
Self-citationOral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Feagan, B. G., & MacDonald, J. K. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub3 · Cited by 177
Self-citationSandborn, W. J., Regula, J., Feagan, B. G., Belousova, E., Jojic, N., Lukas, M., Yacyshyn, B., Krzeski, P., Yeh, C., Messer, C. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.069 · Cited by 169
Self-citationStudies of two novel sulfasalazine analogs, ipsalazide and balsalazide
Chan, R. P., Pope, D. J., Gilbert, A. P., Sacra, P. J., Baron, J. H., & Lennard-Jones, J. E. (1983) · Digestive Diseases and Sciences · doi:10.1007/bf01299921 · Cited by 167
Hanauer, S. B., Sandborn, W. J., Dallaire, C., Archambault, A., Yacyshyn, B., Yeh, C., & Smith-Hall, N. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/862917 · Cited by 164
The mode of action of the aminosalicylates in inflammatory bowel disease
Greenfield, S., Punchard, N. A., TEARE, J. P., & Thompson, R. P. H. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00110.x · Cited by 162
Levine, D. S., Riff, D. S., Pruitt, R. E., Wruble, L. D., Koval, G., Sales, D. J., Bell, J. K., & Johnson, L. K. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05781.x · Cited by 149
Willoughby, C. P., Aronson, J. K., Agback, H., Bodin, N., & Truelove, S. C. (1982) · Gut · doi:10.1136/gut.23.12.1081 · Cited by 149
Vernia, P., Monteleone, G., Grandinetti, G., Villotti, G., Giulio, E. D., Frieri, G., Marcheggiano, A., Pallone, F., Caprilli, R., & Torsoli, A. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005537411244 · Cited by 143
Tang, T., Targan, S. R., Li, Z.-S., Xu, C., Byers, V. S., & Sandborn, W. J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04515.x · Cited by 121
Pruitt, R. E., Hanson, J., Safdi, M. A., Wruble, L. D., Hardi, R., Johanson, J. F., Koval, G., Riff, D. S., Winston, B., Cross, A. J., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.07103.x · Cited by 120
Riley, S. A., Lecarpentier, J., Mani, V., Goodman, M. J., Mandal, B. K., & Turnberg, L. A. (1987) · Gut · doi:10.1136/gut.28.8.1008 · Cited by 112
Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis
Sutherland, L. R., Roth, D. E., & Beck, P. L. (1997) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780030202 · Cited by 108
Increasing Patient Adherence To Gastroenterology Treatment and Prevention Regimens
Levy, R. L., & Feld, A. D. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01200.x · Cited by 105
Sandborn, W. J. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.07092.x · Cited by 105
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis
Kamm, M. A., Lichtenstein, G. R., Sandborn, W. J., Schreiber, S., Lees, K., Barrett, K., & Joseph, R. E. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20580 · Cited by 90
Mansfield, J., Giaffer, M. H., Cann, P. A., Mckenna, D., THORNTON, P. C., & Holdsworth, C. D. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01151.x · Cited by 80
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
Rao, S. S., Dundas, S. A. C., Holdsworth, C. D., Cann, P. A., Palmer, K. R., & Corbett, C. L. (1989) · Gut · doi:10.1136/gut.30.5.675 · Cited by 79
Ito, H., Iida, M., Matsumoto, T., Suzuki, Y., Sasaki, H., Yoshida, T., Takano, Y., & Hibi∥, T. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21193 · Cited by 76
Flourié, B., Hagège, H., Tucat, G., Maetz, D., Hébuterne, X., Kuyvenhoven, J. P., Tg, T., Pierik, M. J., Masclee, A., Dewit, O., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12266 · Cited by 73
Farup, P. G., Hinterleitner, T. A., Lukáš, M., Hébuterne, X., Rachmilewitz, D., Campieri, M., Meier, R. F., Keller, R., Rathbone, B. J., & Oddsson, E. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200108000-00009 · Cited by 66
Interstitial nephritis from mesalazine: case report and literature review
Arend, L. J., & Springate, J. E. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1411-6 · Cited by 64
Gionchetti, P., D’Arienzo, A., Rizzello, F., Manguso, F., Maieron, R., Lecis, P., Valpiani, D., Iaquinto, G., Annese, V., Balzano, A., et al. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155124.74548.61 · Cited by 64
Picco, M. F. (2011) · Yearbook of Gastroenterology · doi:10.1016/j.ygas.2011.07.099 · Cited by 64
Groß, V., Bunganič, I., Александровна, Б. Е., Mikhailova, T. L., Kupčinskas, L., Kiudelis, G., Tulassay, Z., Gabalec, L., Dorofeyev, A. E., Derova, J., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2010.11.006 · Cited by 62
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis
Liang, H., & Ouyang, Q. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.114 · Cited by 60
The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis
Kane, S. V., Brixner, D. I., Rubin, D. T., & Sewitch, M. J. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s1-a.1a · Cited by 60
Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J., Lyne, A., & JOSEPH, R. E. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03688.x · Cited by 58
Zaldaride maleate, an intestinal calmodulin inhibitor, in the therapy of travelers' diarrhea
DuPont, H. L., Ericsson, C. D., Mathewson, J. J., Marani, S. K., Knellwolf, A., & Martinez‐Sandoval, F. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91005-3 · Cited by 56
Guijarro, L. G., Mate, J., Gisbert, J. P., Pérez-Calle, J. L., Marín‐Jiménez, I., Arriaza, E., Olleros, T., Delgado, M., Castillejo, M., Prieto‐Merino, D., et al. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2851 · Cited by 55
Sulphasalazine in ulcerative colitis: in memoriam?
Hayllar, J. S., & Bjarnason, I. (1991) · Gut · doi:10.1136/gut.32.5.462 · Cited by 53
Mahmood, A., Melley, L., Fitzgerald, A. J., Ghosh, S. K., & Playford, R. J. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02436.x · Cited by 50
Gibson, P. G., Fixa, B., Pekárková, B., Bátovský, M., Radford‐Smith, G. L., TIBITANZL, J., Gabalec, L., Florin, T. H., & Greinwald, R. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02861.x · Cited by 49
Elseviers, M. M., D’Haens, G., Lerebours, É., Plane, C., Stolear, J.-C., Riegler, G., Capasso, G., Outryve, M. V., Mishevska-Mukaetova, P., Djuranovic, S. P., et al. (2004) · Clinical Nephrology · doi:10.5414/cnp61083 · Cited by 48
D’Haens, G., Sandborn, W. J., Zou, G., Stitt, L., Rutgeerts, P. J., Gilgen, D., Jairath, V., Hindryckx, P., Shackelton, L. M., Vandervoort, M. K., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14164 · Cited by 48
Self-citationThe efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Kane, S. V., & Bjorkman, D. J. (2003) · PubMed · Cited by 47
Rubin, D. T., Cohen, R. D., Sandborn, W. J., Lichtenstein, G. R., Axler, J. L., Riddell, R. H., Zhu, C., Barrett, A. C., Bortey, E. B., & Forbes, W. P. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx052 · Cited by 45
Acute Interstitial Nephritis Associated with the Use of Mesalazine in Inflammatory Bowel Disease
Frandsen, N. E., Saugmann, S., & Marcussen, N. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000064461 · Cited by 43
Guslandi, M., Frego, R., Viale, E., & Testoni, P. A. (2002) · Canadian Journal of Gastroenterology · doi:10.1155/2002/307218 · Cited by 42
Orchard, T., van der Geest, S. A. P., & Travis, S. P. L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04620.x · Cited by 39
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis
ROBINSON, M. G., Hanauer, S., Hoop, R., et al. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00157.x · Cited by 35
Connolly, M. P., Poole, C., Currie, C. J., Marteau, P. R., & Nielsen, S. K. (2009) · Digestion · doi:10.1159/000235916 · Cited by 27
Forbes, A., Damluji, A. A., Ashworth, S., Bramble, M. G., Herbert, K., Ho, J., Kang, J. Y., Przemioslo, R. T., & Shetty, A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02442.x · Cited by 25
Irvine, E. J., Yeh, C., Ramsey, D. J., STIRLING, A. L., & Higgins, P. D. R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03854.x · Cited by 25
Different therapy for different types of ulcerative colitis in China
Jiang, X.-L. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i10.1513 · Cited by 21
Dignass, A. U., Schnabel, R., Romatowski, J. A., Pavlenko, V. V., Dorofeyev, A. E., Derova, J., Jonaitis, L. V., Dilger, K., Nacak, T., Greinwald, R., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617703842 · Cited by 14
Yamamoto, T., Umegae, S., & Matsumoto, K. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.11.016 · Cited by 12
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
Hanauer, S. B., Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J., Lees, K., Barrett, K., Karlstadt, R. G., Diebold, R., & Joseph, R. E. (2009) · PubMed Central · Cited by 10
Safety and Activity of Dersalazine Sodium in Patients with Mild-to-moderate Active Colitis
Pontes, C., Vives, R., Torres, F., & Panés, J. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000166 · Cited by 10
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationLamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Le Berre, C., Honap, S., & Peyrin-Biroulet, L. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00966-2 · Cited by 1,643
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Metadata
- Authors
- Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-04-21
- Volume
- 4
- Pages
- CD000543-CD000543
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1930299866
- Cited by
- 494
- References
- 103
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.